Under construction – not a live service
Sign in
Not yet taking people in ChinaNo phase

Effectiveness of Ginkgo Diterpene Lactone Meglumine in Acute Ischemic Stroke

Key facts

Where
Changchun, Harbin, Jining, Lanzhou, Nanjing, Xian, Xuzhou, and Zhengzhou, ChinaSee the 10 sites

Where in China

  • The First Hospital of Jilin UniversityChangchun, ChinaNo longer taking part
  • Harbin Second HospitalHarbin, ChinaNo longer taking part
  • The Fourth Affiliated Hospital of Harbin Medical UniversityHarbin, ChinaNo longer taking part
  • Affiliated Hospital of Jining Medical UniversityJining, ChinaNo longer taking part
  • Gansu Provincial People's HospitalLanzhou, ChinaNo longer taking part
  • Jiangsu Geriatric HospitalNanjing, ChinaNo longer taking part
  • Jiangsu Provincial Hospital of Traditional Chinese MedicineNanjing, ChinaNo longer taking part
  • Xian Changan District HospitalXian, ChinaNo longer taking part
  • Xuzhou Hospital of Traditional Chinese MedicineXuzhou, ChinaNo longer taking part
  • Henan Provincial People's HospitalZhengzhou, ChinaNo longer taking part

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
Ying Gao
Trial code
NCT06861426
Record updated
6 March 2025
Original description
The primary purpose of this study is to investigate the effectiveness of Ginkgo Diterpene Lactone Meglumine (GDLM) for patients with acute ischemic stroke (AIS) in real-world settings.Read full original descriptionShow less

Patients with Acute Ischemic Stroke Receiving Ginkgo Diterpene Lactone Meglumine: a Patient Registry

The primary purpose of this study is to investigate the effectiveness of Ginkgo Diterpene Lactone Meglumine (GDLM) for patients with acute ischemic stroke (AIS) in real-world settings.

Inclusion: aged ≥18 years, regardless of gender; within 48 hours of stroke onset of ischemic stroke; patient or their legally authorized representative (LAR) has signed informed consent or legally authorized oral consent with documentation.

Exclusion: mRS score of 2 or more prior to onset; inability to comply with study procedures due to documented psychiatric disorders or severe cognitive impairment; total hospital stay less than 7 days; use of other ginkgo-derived preparations except GDLM; current or planned participation in any other interventional clinical trials.

ClinicalTrials.gov NCT06861426

Under construction, not live – Effectiveness of Ginkgo Diterpene Lactone Meglumine in Acute Ischemic Stroke (NCT06861426) – Frontlight Research